Logo image of ATOS

ATOSSA THERAPEUTICS INC (ATOS) Stock Fundamental Analysis

NASDAQ:ATOS - Nasdaq - US04962H5063 - Common Stock - Currency: USD

0.7952  -0.04 (-5.32%)

After market: 0.8012 +0.01 (+0.75%)

Fundamental Rating

3

Taking everything into account, ATOS scores 3 out of 10 in our fundamental rating. ATOS was compared to 571 industry peers in the Biotechnology industry. ATOS has a great financial health rating, but its profitability evaluates not so good. ATOS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ATOS has reported negative net income.
In the past year ATOS has reported a negative cash flow from operations.
In the past 5 years ATOS always reported negative net income.
ATOS had a negative operating cash flow in each of the past 5 years.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of ATOS (-33.86%) is better than 63.23% of its industry peers.
ATOS's Return On Equity of -36.52% is fine compared to the rest of the industry. ATOS outperforms 73.89% of its industry peers.
Industry RankSector Rank
ROA -33.86%
ROE -36.52%
ROIC N/A
ROA(3y)-22.56%
ROA(5y)-47.75%
ROE(3y)-23.61%
ROE(5y)-56.71%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

ATOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

ATOS has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ATOS has been increased compared to 5 years ago.
ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

An Altman-Z score of 7.17 indicates that ATOS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.17, ATOS belongs to the best of the industry, outperforming 82.95% of the companies in the same industry.
ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.17
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

ATOS has a Current Ratio of 13.30. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
ATOS's Current ratio of 13.30 is amongst the best of the industry. ATOS outperforms 86.50% of its industry peers.
ATOS has a Quick Ratio of 13.30. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.30, ATOS belongs to the top of the industry, outperforming 86.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.3
Quick Ratio 13.3
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ATOS have decreased by -4.17% in the last year.
EPS 1Y (TTM)-4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATOS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.59% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.15%
EPS Next 2Y-1%
EPS Next 3Y-5.41%
EPS Next 5Y31.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A cheap valuation may be justified as ATOS's earnings are expected to decrease with -5.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1%
EPS Next 3Y-5.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (2/21/2025, 8:02:10 PM)

After market: 0.8012 +0.01 (+0.75%)

0.7952

-0.04 (-5.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-31 2025-03-31/amc
Inst Owners27.48%
Inst Owner Change9.55%
Ins Owners0.04%
Ins Owner Change0%
Market Cap100.04M
Analysts82.22
Price Target6.12 (669.62%)
Short Float %7.36%
Short Ratio10.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.85%
Min EPS beat(2)-3.8%
Max EPS beat(2)13.5%
EPS beat(4)2
Avg EPS beat(4)-4.88%
Min EPS beat(4)-55.7%
Max EPS beat(4)26.47%
EPS beat(8)5
Avg EPS beat(8)0%
EPS beat(12)9
Avg EPS beat(12)4.56%
EPS beat(16)11
Avg EPS beat(16)-12.41%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.09%
EPS NQ rev (1m)-5.55%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.96%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.86%
ROE -36.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.56%
ROA(5y)-47.75%
ROE(3y)-23.61%
ROE(5y)-56.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.3
Quick Ratio 13.3
Altman-Z 7.17
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)136.96%
Cap/Depr(5y)90.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y18.15%
EPS Next 2Y-1%
EPS Next 3Y-5.41%
EPS Next 5Y31.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.76%
OCF growth 3YN/A
OCF growth 5YN/A